The Moving Average Convergence Divergence (MACD) for GILD turned positive on October 14, 2026. Looking at past instances where GILD's MACD turned positive, the stock continued to rise in 39 of 54 cases over the following month. The odds of a continued upward trend are 72%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on GILD as a result. In 56 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 67%.
Following a +2.38% 3-day Advance, the price is estimated to grow further. Considering data from situations where GILD advanced for three days, in 215 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
The Aroon Indicator entered an Uptrend today. In 167 of 275 cases where GILD Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
The 10-day RSI Indicator for GILD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 39 similar instances where the indicator moved out of overbought territory. In 17 of the 39 cases, the stock moved lower in the following days. This puts the odds of a move lower at 44%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 27 of 63 cases where GILD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 43%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GILD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 47%.
GILD broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 6 (best 1 - 100 worst), indicating outstanding price growth. GILD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 32 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.495) is normal, around the industry mean (-1.421). GILD's P/E Ratio (-63.943) is considerably lower than the industry average of (21.700). Projected Growth (PEG Ratio) (2.263) is also within normal values, averaging (5.738). Dividend Yield (0.020) settles around the average of (0.038) among similar stocks. P/S Ratio (6.053) is also within normal values, averaging (4.033).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
SNY moved above its 50-day moving average on October 29, 2026 date and that indicates a change from a downward trend to an upward trend. In 30 of 51 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 16, 2026. You may want to consider a long position or call options on SNY as a result. In 55 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 56%.
The Moving Average Convergence Divergence (MACD) for SNY just turned positive on October 15, 2026. Looking at past instances where SNY's MACD turned positive, the stock continued to rise in 25 of 46 cases over the following month. The odds of a continued upward trend are 54%.
The 10-day moving average for SNY crossed bullishly above the 50-day moving average on November 02, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 47%.
Following a +0.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where SNY advanced for three days, in 154 of 303 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.
The Aroon Indicator entered an Uptrend today. In 160 of 284 cases where SNY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 14 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SNY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 52%.
SNY broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating fairly steady price growth. SNY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock slightly worse than average.
The Tickeron SMR rating for this company is 81 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.629) is normal, around the industry mean (-1.421). P/E Ratio (28.596) is within average values for comparable stocks, (21.700). SNY's Projected Growth (PEG Ratio) (27.976) is very high in comparison to the industry average of (5.738). SNY's Dividend Yield (0.169) is considerably higher than the industry average of (0.038). P/S Ratio (1.829) is also within normal values, averaging (4.033).
GILD | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 25 | 46 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 32 Undervalued | 88 Overvalued | |
PROFIT vs RISK RATING 1..100 | 5 | 64 | |
SMR RATING 1..100 | 96 | 81 | |
PRICE GROWTH RATING 1..100 | 6 | 41 | |
P/E GROWTH RATING 1..100 | 100 | 7 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
GILD's Valuation (32) in the Biotechnology industry is somewhat better than the same rating for SNY (88) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than SNY’s over the last 12 months.
GILD's Profit vs Risk Rating (5) in the Biotechnology industry is somewhat better than the same rating for SNY (64) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than SNY’s over the last 12 months.
SNY's SMR Rating (81) in the Pharmaceuticals Major industry is in the same range as GILD (96) in the Biotechnology industry. This means that SNY’s stock grew similarly to GILD’s over the last 12 months.
GILD's Price Growth Rating (6) in the Biotechnology industry is somewhat better than the same rating for SNY (41) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than SNY’s over the last 12 months.
SNY's P/E Growth Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for GILD (100) in the Biotechnology industry. This means that SNY’s stock grew significantly faster than GILD’s over the last 12 months.
| GILD | SNY | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 44% | 1 day ago 36% |
| Stochastic ODDS (%) | 1 day ago 43% | 1 day ago 53% |
| Momentum ODDS (%) | 1 day ago 67% | 1 day ago 56% |
| MACD ODDS (%) | 1 day ago 72% | 1 day ago 54% |
| TrendWeek ODDS (%) | 1 day ago 44% | 1 day ago 53% |
| TrendMonth ODDS (%) | 1 day ago 64% | 1 day ago 49% |
| Advances ODDS (%) | 2 days ago 64% | 1 day ago 51% |
| Declines ODDS (%) | 6 days ago 47% | about 1 month ago 52% |
| BollingerBands ODDS (%) | 1 day ago 45% | 1 day ago 50% |
| Aroon ODDS (%) | 1 day ago 61% | 1 day ago 56% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GILD’s FA Score shows that 3 FA rating(s) are green while SNY’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GILD’s TA Score shows that 4 TA indicator(s) are bullish while SNY’s TA Score has 6 bullish TA indicator(s).
GILD (@Pharmaceuticals: Major) experienced а -2.72% price change this week, while SNY (@Pharmaceuticals: Major) price change was +6.40% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.46%. For the same industry, the average monthly price growth was +2.44%, and the average quarterly price growth was +7.11%.
GILD is expected to report earnings on Feb 04, 2027.
SNY is expected to report earnings on Jan 29, 2027.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with PFE. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To SNY | 1D Price Change % | ||
|---|---|---|---|---|
| SNY | 100% | +0.41% | ||
| PFE - SNY | 47% Loosely correlated | +0.31% | ||
| GILD - SNY | 43% Loosely correlated | -0.67% | ||
| AMGN - SNY | 43% Loosely correlated | +0.62% | ||
| JNJ - SNY | 36% Loosely correlated | -0.13% | ||
| MRK - SNY | 35% Loosely correlated | -0.59% | ||
More | ||||